New pill for chronic hives tested in real-world study
NCT ID NCT07358780
First seen Jan 25, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study follows 505 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib. The goal is to measure symptom control and safety over 24 months, giving doctors a clearer picture of how this newer treatment performs outside of controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Cleaver Dermatology
RECRUITINGKirksville, Missouri, 63501, United States
Conditions
Explore the condition pages connected to this study.